Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?

Diana L Castillo-Carranza1,2
Marcos J Guerrero-Muñoz1,2
Rakez Kayed1–3

1Mitchell Center for Neurodegenerative Diseases, 2Departments of Neurology, Neuroscience, and Cell Biology, 3Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA

Abstract: Alzheimer’s disease (AD) is characterized by the presence of amyloid plaques composed mainly of amyloid-β (Aβ) protein. Overproduction or slow clearance of Aβ initiates a cascade of pathologic events that may lead to formation of neurofibrillary tangles, neuronal cell death, and dementia. Although immunotherapy in animal models has been demonstrated to be successful at removing plaques or prefibrillar forms of Aβ, clinical trials have yielded disappointing results. The lack of substantial cognitive improvement obtained by targeting Aβ raises the question of whether or not this is the correct target. Another important pathologic process in the AD brain is tau aggregation, which seems to become independent once initiated. Recent studies targeting tau in AD mouse models have displayed evidence of cognitive improvement, providing a novel therapeutic approach for the treatment of AD. In this review, we describe new advances in immunotherapy targeting Aβ peptide and tau protein, as well as future directions.

Keywords: immunotherapy, Alzheimer’s disease, β-amyloid, tau

Introduction

Alzheimer’s disease (AD) is a complex, debilitating disorder and the most common cause of dementia affecting those over the age of 65 years. Currently available drugs for the treatment of AD only provide relief of symptoms with no effect on the course of the disease. As the longevity of the worldwide population increases, the amount of people susceptible to AD will continue to rise. Therefore, there is an urgent need to develop new therapeutic strategies to modify or prevent the progression of AD. The cause or causes of sporadic AD are unknown. Histopathologic features of the disease are accumulation of extracellular amyloid plaques, mainly composed of amyloid β (Aβ) peptide and intracellular neurofibrillary tangles (NFTs) composed of tau protein. Aβ peptide is derived from amyloid precursor protein (APP) and while missense mutations in APP or in presenilin (PS) genes, PS1 and PS2, can cause familial forms of AD, the sporadic form is the most prevalent, representing 95% of all cases. Regardless of the cause of AD, the consequence is accumulation of Aβ monomers, which eventually aggregate, forming oligomers, fibrils, and finally large metastable plaques.

For over two decades, the Aβ peptide has been considered the main culprit of AD. According to the amyloid cascade hypothesis, Aβ peptide accumulates into plaques, triggering a series of events leading to formation of NFTs, neuronal cell death, and dementia. However, this theory fails to explain the discrepancy between amyloid plaque deposition and cognitive impairment in AD. The lack of correlation comes from post-mortem tissue of patients included in the first clinical trial. Although immunization...
against Aβ induced a reduction of amyloid plaques, the patients had severe dementia before death. Furthermore, it seems likely that neurodegeneration may begin prior to amyloid deposition. Moreover, the presence of amyloid plaques in the brains of cognitively normal adults indicates that another entity is involved in cognitive decline. Prefibrillar forms of Aβ or oligomers have been identified in AD brains. Recent evidence suggests that Aβ oligomers and not fibrils are the primary toxic species in AD. Toxicity of oligomers was demonstrated in vitro and in vivo.

Importantly, observations from post-mortem tissue revealed that tau pathology correlates better with the severity of dementia. Moreover, it has been reported that soluble forms of Aβ correlate with the onset of the disease only in the presence of tau. Additionally, tau pathology occurs in brain areas lacking amyloid plaques. These findings suggest that tau mediates Aβ toxicity. However, mechanistic relationships between Aβ deposition and tau pathology remain contentious. Despite the evidence that tau pathology contributes to disease progression, therapeutic approaches have been concentrated almost entirely on modulating Aβ production or accumulation. These interventions include: reduction of APP processing by blocking the β or γ secretases; prevention of Aβ aggregation; and promoting Aβ clearance by immunotherapy. However, γ secretase inhibitors have been found to have toxic effects, while β secretase inhibitors are high molecular weight compounds with limited ability to cross the blood–brain barrier. On the other hand, immunotherapeutic approaches targeting Aβ for the treatment of AD failed to slow cognitive decline. The disappointing results obtained by lowering Aβ questioned whether or not Aβ is the correct target. This review provides a description of new advances in Aβ and tau immunotherapy as well as future directions.

**Targeting Aβ assemblies by immunotherapy**

In AD, Aβ converts from its soluble form to β-sheet-rich, toxic oligomers and highly organized fibrils, which eventually assemble into plaques. However, the toxic role of Aβ aggregates found in AD brains remains unclear. For a long time, senile plaques were considered to be the toxic species in AD. In the brain cortex of aged rhesus monkeys, Aβ fibrils induced toxicity of neurons in the vicinity of plaques. Toxicity of plaques was also observed previously using longitudinal in vivo multiphoton imaging in mice. Plaque formation was fast and followed by neuritic changes. However, recent evidence from animal models suggests that plaque accumulation has a protective rather than toxic effect. Animal models exposed to an enriched environment showed cognitive improvement associated with an increase in plaque load, confirming the lack of correlation between brain amyloid plaque deposition and cognition in AD.

**Amyloid plaques**

Immunotherapeutic approaches to treat AD have been well executed in various mouse models. These approaches can be broadly classified as either active or passive immunization strategies. In 1999, Schenk et al published the first active immunization study in the PDAPP transgenic mouse model. Initial findings revealed a reduction of plaque deposition in aged mice after administration of Aβ-42. Treatment in young mice prevented Aβ plaque formation. No signs of damage were observed in the brains of treated animals. Later, two other groups reported the immunization of different AD mouse models using aggregated Aβ-42. Immunization of TgCRND8 mice resulted in a reduction in amyloid plaque load. No changes in total Aβ levels were observed. Furthermore, improvement in cognition was observed by evaluation with the Morris water maze. In a separate study, immunization of Tg2576 and Tg2576-PS1 mice also recapitulated the effect of the Aβ-42 treatment described previously. In these cases, active immunotherapy had beneficial effects on cognition, which correlated with reduction of amyloid plaque burden. Not only were full Aβ1–42 immunizations effective, but fragments of Aβ peptide including tandems of Aβ(1–15) also induced reduction of plaque load and lowered levels of Aβ-40 and Aβ-42 in the brain, which correlated with an efflux of Aβ to the blood. Moreover, combination of Aβ fragments with either diphtheria toxoid or tetanus toxoid was used to stimulate the immune system, while avoiding an Aβ-specific T-cell response. Afterwards, several active immunization studies reproduced the same results using Aβ peptide in different AD models including rats, nonhuman primates, and mice. Contrary to other active immunizations, Austin et al described no improvement in memory after several months of treatment with Aβ-42. This work suggests that immunization could be more beneficial in the early stages of the disease. Adverse effects were also reported in old lemurs after Aβ immunization, including microbleeds and iron deposits in the choroid plexus.

Passive immunizations have also been performed in animal models of AD. Although the use of antibodies represents a safer alternative to active immunotherapy, treatment may need to be administered frequently in order to
reach the necessary concentration in serum to be effective. It has been estimated that only 0.1% of the antibody in blood crosses the blood–brain barrier. Studies in mice immunized with mouse monoclonal antibodies against Aβ peptide indicated that the antibody can cross the blood–brain barrier and reduce amyloid plaques, as well as levels of soluble Aβ-42. However, removal of plaques in the PDAPP mouse does not necessarily require the antibody to enter the brain. Peripherally administered m266 antibody, that recognizes Aβ1–28, clears Aβ deposits from the brain with no evidence of antibody-plaque interaction. These findings suggest that removal of amyloid pathology from the brain alters the Aβ dynamics inducing protein efflux to plasma.

Immunization of Tg2576 mice with BAM-10 antibody that recognizes Aβ1–12 fully reversed memory deficits, as demonstrated by the Morris water maze task. However, treatment with BAM-10 had an insignificant effect on reduction of soluble Aβ levels in the mouse brain. Researchers propose that treatment causes BAM-10 to enter the central nervous system, reversing deleterious effects of small Aβ assemblies that interfere with cognitive function, thus restoring normal memory in Tg2576 mice. Subsequently, others failed to find a correlation between performance in behavioral tests and amyloid pathology. Although passive immunization reverses cognitive deficits in AD mouse models, some antibodies induce vascular pathology, including intracerebral hemorrhage. When PDAPP mice were immunized with an anti-Aβ1–5 antibody known as 3D6, it interacted with soluble and insoluble Aβ, as well as induced removal of Aβ deposits from the vasculature. This treatment increased microhemorrhage and Aβ deposits in capillaries, but side effects were eventually resolved. Antibodies against amyloid plaques have also been developed. Chronic treatment of PDAPP mice with an antibody that recognizes Aβ42 lowered pre-existing plaques without microhemorrhage. However, treatment was less effective at preventing plaque deposition in immunized mice. This phenomenon is associated with those antibodies that bind Aβ in plaques. However, the mechanism by which immunization reduced plaques is not understood. It has been suggested that neoangiogenesis, a key event underlying plaque formation in AD, can be modulated by removal of plaques in mice immunized with Aβ peptide by inducing reversion of hypervascularization. Additionally, two possible mechanisms of antibody-mediated removal of amyloid plaque have been proposed. These are microglia activation and the peripheral sink hypothesis. Microglia activation implies that antibody enters the brain to stimulate phagocytosis of the antibody-Aβ complex. On the other hand, the sink mechanism does not require the antibody to enter the brain, in that a peripheral sink is created when the antibodies in serum alter the equilibrium of Aβ across the blood–brain barrier, inducing an efflux of proteins from brain to blood. Both mechanisms have been demonstrated in preclinical studies.

**Clinical trials**

Although the first clinical trial using immunotherapy for AD was stopped because of adverse effects, some are currently in progress (Table 1). The first active immunization in humans consisted of a mixture of Aβ42 peptide and adjuvant QS-21, known as AN1792. Treatment with this preparation did not find significant differences between the antibody and placebo groups in a variety of behavioral tests, including Alzheimer’s Disease Assessment Scale-cognitive (ADAS-Cog), Disability Assessment for Dementia, Clinical Dementia Rating, Mini-Mental State Examination, or Clinical Global Impression of Change. Although the Phase I trial showed good tolerability, the Phase IIa trial was interrupted because 6% of immunized patients developed acute meningocerebralitis. A follow-up of patients treated with AN1792 in a Phase I trial showed clearance of amyloid plaques without preventing progression of the disease, and after 5 years there was no evidence of reduction of neurodegeneration. Major adverse events observed with AN1792 include meningocerebralitis and cerebral microhemorrhage. Post-mortem analysis of encephalitis cases revealed that brain infection was associated with T-cell activation. This seems to be related to the sequence of the protein, given that the Aβ-carboxyl terminus contains epitopes for T-cells. Therefore, different N-terminal Aβ peptides like AD0, AD02, ACC-001, CAD106, and ACI-24 were developed and are now in Phase II clinical trials. Affitopes (AD01 and AD02) contain a six amino acid peptide that mimics part of the native Aβ N-terminus while ACC-001 is a vaccine composed of a seven amino acid fragment of the Aβ N-terminal conjugated to a mutated diphtheria toxin protein known as CRM197. Patients immunized with the N-terminal of the Aβ peptide called CAD106 had some adverse effects, including nasopharyngitis and injection site erythema. Nine patients experienced serious adverse events, none of which were related to the peptide. This treatment increased total Aβ levels and reduced free Aβ in plasma. However, no significant changes in Aβ or tau levels were observed in cerebrospinal fluid. Another active immunization is the ACI-24 vaccine, consisting of a liposome-based vaccine with a tetra-palmitoylated Aβ1–15 fragment. Preclinical studies in APP-V717IxPS-1 (APPxPS-1) double transgenic mice restored cognitive memory and reduced brain amyloid load and...
microbleeds. In humans, ACI-24 stimulated the immune system to produce β-sheet conformation-specific antibodies. A Phase I trial has been designed to identify the best dose of vaccine to be used in a Phase II trial.64 No results have been posted as yet.

Recent advances in preclinical studies in animals have encouraged the development of humanized antibodies for clinical trials. These antibodies have been developed as a promising safe alternative strategy in clinical trials. One of them, bapineuzumab, is a humanized monoclonal immunoglobulin G1 (IgG1) antibody that recognizes the Aβ1–5 region. Preclinical studies showed a reduced plaque burden in transgenic mice.60 Phase II studies showed that immunization with bapineuzumab significantly reduced cerebral Aβ levels, hyperphosphorylated tau in cerebrospinal fluid, and total tau levels when compared with placebo-treated patients.65-67 However, this antibody did not show significant differences in AD patients compared with the placebo group. Post hoc analysis suggested a modest effect in apolipoprotein (Apo) ε4 noncarriers, although 9.7% of patients showed vasogenic cerebral edema.68 In Phase III clinical trials, neither AD patients carrying the Apoε4 allele nor those who were noncarriers showed improvement.69 A second antibody that has been used in clinical trials is solanezumab, a humanized monoclonal IgG1 antibody that recognizes the Aβ13–28 region (266 mouse monoclonal antibody), and has little affinity for fibrillar material. Although the antibody was found to be safe, with no features of meningoencephalitis, microhemorrhage, or vasogenic edema observed in Phase II clinical trials,70 treatment with solanezumab did not induce improvement in cognition.70,71 A Phase III study reported a 34% slowing of decline on the ADAS-cog and Mini-Mental State Examination and a slowing of functional decline on the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (P=0.057) at 80 weeks in patients with mild AD. The treatment caused an increase in total Aβ1–40 and Aβ1–42 in cerebrospinal fluid, and lower cerebrospinal fluid levels of free Aβ1–40. However, positron emission tomography (PET) scan did not show a significant reduction of amyloid plaques. New results from a Phase III clinical trial did not show significant differences in biomarkers of neuronal damage in cerebrospinal fluid.69

Gantenerumab is a humanized monoclonal IgG1 antibody (Aβ1–11) that binds specifically to amyloid plaques. Treatment with this antibody reduced amyloid plaques in patients with mild to moderate AD, but no cognitive improvement was reported. Furthermore, treatment given to AD patients who were Apoε4 carriers resulted in reversible vasogenic edema.72 A Phase III clinical trial is now underway. Another monoclonal humanized antibody is crenezumab, an IgG4 that recognizes the Aβ12–23 region. Preclinical research using this antibody in AD mouse models

**Table I Immunotherapeutic strategies for the treatment of Alzheimer’s disease**

<table>
<thead>
<tr>
<th>Immunization</th>
<th>Name</th>
<th>Drug</th>
<th>Clinical trials</th>
<th>Effects on biomarkers</th>
<th>Major adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active</td>
<td>AN1792</td>
<td>Aβ1–42 with Q21 as adjuvant</td>
<td>Phase II</td>
<td>Clearence of amyloid plaques</td>
<td>Meningoencephalitis and cerebral microhemorrhage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No results posted</td>
<td>No results posted</td>
</tr>
<tr>
<td></td>
<td>Aftitope AD02</td>
<td>Peptide mimicking B-cell epitope peptide, Aβ1–6 with no sequence similarities</td>
<td>Phase II ongoing</td>
<td>No results posted</td>
<td>No results posted</td>
</tr>
<tr>
<td></td>
<td>ACC-001</td>
<td>Aβ1–6 conjugated to the mutated diphtheria toxin protein CRM19</td>
<td>Phase II ongoing</td>
<td>Increase of total Aβ1 levels and reduced free Aβ in plasma</td>
<td>None related to immunized group</td>
</tr>
<tr>
<td></td>
<td>CAD106</td>
<td>B-cell epitope peptide, Aβ1–6, which is coupled to a bacteriophage coat protein</td>
<td>Phase II</td>
<td>No results posted</td>
<td>No results posted</td>
</tr>
<tr>
<td></td>
<td>ACI-24</td>
<td>Liposome-based vaccine with tetra-palmitoylated Aβ1–15</td>
<td>Phase I/IIa</td>
<td>Reduction of amyloid plaques</td>
<td>Vasogenic cerebral edema</td>
</tr>
<tr>
<td>Passive</td>
<td>Bapineuzumab</td>
<td>IgG1 isotype targeting Aβ1–5</td>
<td>Phase II</td>
<td>Reduction of cerebral Aβ, CSF p-tau, and total tau levels</td>
<td>None related to immunized group</td>
</tr>
<tr>
<td></td>
<td>Solanezumab</td>
<td>IgG1 isotype targeting Aβ13–28</td>
<td>Phase II</td>
<td>Increase in CSF Aβ1–40, Aβ1–42 levels and reduced CSF levels of free Aβ1–40</td>
<td>Vasogenic edema</td>
</tr>
<tr>
<td></td>
<td>Gantenerumab</td>
<td>IgG1 isotype targeting Aβ1–11</td>
<td>Small group of patients</td>
<td>Reduction of amyloid plaques</td>
<td>Vasogenic edema</td>
</tr>
<tr>
<td></td>
<td>Crenezumab</td>
<td>IgG4 isotype targeting Aβ12–23</td>
<td>Phase I</td>
<td>Increase in total plasma Aβ1–40 and total Aβ1–42 levels</td>
<td>None related to immunized group</td>
</tr>
<tr>
<td></td>
<td>IVIG</td>
<td>Pool mixture of immunoglobulin from healthy people</td>
<td>Phase II/III</td>
<td>Reduction of amyloid plaques and plasma Aβ1–42 levels</td>
<td>Ischemic stroke and microbleeds</td>
</tr>
</tbody>
</table>

**Abbreviations:** Aβ, amyloid beta; CSF, cerebrospinal fluid; Ig, immunoglobulin; IVIG, intravenous immunoglobulin; p-tau, phosphorylated tau.
showed reduction of amyloid plaque pathology and cognitive improvement as assessed by the novel object recognition test. More relevantly, the IgG4 isotype of crenezumab induced milder activation of microglia and less release of the proinflammatory cytokine, tumor necrosis factor-alpha, compared with the IgG1 isotype of the same antibody. Finally, a Phase I study did not show signs of vasogenic edema even in ApoE4 carriers. This antibody is now in a Phase II clinical trial.

Although some clinical trials are still ongoing, it is clear from the results observed thus far that this approach does not succeed in stopping disease progression in AD patients, and this may be the consequence of starting the treatment when pathologic events had already developed in the brain. Previous studies showed that changes in the brain start two decades before the onset of clinical symptoms, and this finding suggests that therapeutic intervention earlier in the course of the disease may provide more clinical benefits.

Upcoming human studies will evaluate prevention of the disease in individuals at risk for AD. These include the Dominantly Inherited Alzheimer Network study, the Alzheimer Prevention Initiative, and the study for Treatment of Asymptomatic Alzheimer’s Disease. The Dominantly Inherited Alzheimer Network study will analyze individuals from families with autosomal dominant AD who are carriers of mutations in APP, PSEN1, or PSEN2 genes. Patients will be treated with solanezumab, gantenerumab, or a beta secretase inhibitor (LY2886721). The Alzheimer Prevention Initiative study will investigate a group of families in Antioquia, Colombia, who are carriers of a rare autosomal dominant mutation in the PS1 gene (E280A) responsible for familial Alzheimer’s disease. In one clinical trial, cognitively normal individuals carrying the mutation in PSEN1 will be treated with the monoclonal antibody crenezumab. The second trial will investigate cognitively normal individuals homozygous for the ApoE4 allele associated with late-onset AD. For the Treatment of Asymptomatic Alzheimer’s Disease study, older patients who are not carriers of genetic mutation but whose brains have Aβ deposition as measured by PET scan, will be immunized with the solanezumab antibody.

**Aβ oligomers**

Although amyloid plaques are a hallmark of AD, oligomers are considered to be mediators of the early state of the disease. The toxicity of oligomers has been widely demonstrated in cells both in culture and in vivo. Different oligomeric entities have been found in the AD brain, including dimer, trimer, dodecamer (Aβ*56), and high order oligomers. Synaptic dysfunction is one of the effects induced by dimers and Aβ*56 when injected into the brain. These findings indicate that oligomers interfere with normal synaptic function, inducing cognitive deficit. Analyses of human brain and cerebrospinal fluid indicate that Aβ*56 levels correlate with neuronal dysfunction before onset. These findings suggest that removal of oligomeric assemblies is important to prevent interaction of Aβ with synapses.

Immunization targeting Aβ oligomers has been performed by vaccination of Tg2576 mice with amyloid oligomimics, prepared from a nonhuman random sequence assembled in to amyloid oligomer like structures, immunization with this antigen improved cognitive function, reduced total plaque load with a much lower incidence of microhemorrhage compared with Aβ antigens. These findings suggest that other alternatives may be used in order to avoid the autoimmune side effects produced by Aβ peptide. Furthermore, chronic immunization as well as acute treatment with m266 antibody in PDAPP mice prevented age-related memory deficits, but no effect on Aβ plaque load was observed either in the cortex or hippocampus, suggesting that removal of soluble Aβ, but not plaques, is sufficient to induce improvement in cognition. Exogenous and endogenous antibodies against Aβ oligomers prevented long-term potentiation in vivo. Additionally, vaccination of SAMP8 mice with A8 monoclonal antibody reduced low molecular weight Aβ oligomers and tau phosphorylation (pSer404) while improving cognitive function. Immunization with an antibody that recognizes dimers, small oligomers, and mature plaques also improved learning and memory deficits in Tg2576 mice. Treatment of APP mice with globular-specific antibody improved cognitive function and spine density.

Treatment for Aβ oligomers has also been performed in humans. A small group of AD patients was treated with a pooled mixture of immunoglobulin from healthy people containing antibodies against Aβ oligomers and fibrils. In a pilot study, one of five AD patients treated with intravenous immunoglobulins showed stabilization and modest cognitive improvement. Aβ levels were reduced in cerebrospinal fluid and increased in plasma. Intravenous immunoglobulins were also used in eight patients with mild AD for 6 months, stopped for 3 months, and then resumed for another 9 months. Treated patients showed cognitive improvement as assessed by Mini-Mental State Examination at 6 months. After each treatment, Aβ decreased in cerebrospinal fluid and increased in plasma. Importantly, no serious adverse effects were reported in this study. However, in a Phase II clinical trial, evaluation of 58 AD patients did not reveal significant cognitive improvement. Moreover, no changes in concentrations of Aβ-40, Aβ-42, total tau, or p-tau were
observed in cerebrospinal fluid. Further, one patient had an ischemic stroke (a known side effect of intravenous immunoglobulins), while 14% of patients had incident microbleeds, which were not seen in the placebo group. In a randomized, double blind, placebo-controlled Phase III clinical trial, treatment with intravenous immunoglobulins for 18 months in people with mild to moderate AD did not show significant cognitive improvement in ADAS-Cog or the Alzheimer’s Disease Cooperative Study-Activities of Daily Living tests. However, an Apo-e4 carrier subgroup receiving intravenous immunoglobulins at 400 mg/kg every 2 weeks (n=87) showed cognitive improvement on the Modified Mini-Mental State Examination and Trails B test. PET scan analysis with flortetapir showed a reduction in brain fibrillar amyloid in patients treated with an intravenous immunoglobulin preparation at 400 mg/kg every 2 weeks. Significant reductions in plasma Aβ-42 levels, but not Aβ-40 levels, were observed in patients treated with intravenous immunoglobulins. This group showed higher levels of anti-oligomer and anti-fibril antibodies in cerebrospinal fluid but no effect was observed for tau and phosphorylated tau levels in cerebrospinal fluid. The results obtained failed to meet the primary endpoints of slowing cognitive and functional decline.

Implication of tau pathology in AD
An unsolved question in AD is the relationship between Aβ and tau pathology. Tau has long been considered to be the secondary effect of Aβ pathology. However, new evidence suggests that tau pathology may appear early in life, and perhaps before Aβ. Tau pathology is another important hallmark of AD and perhaps the most promising target. It is widely expressed in the central nervous system, and is required for microtubule assembly, axonal transport, and neurite outgrowth. Further, it is known that tau pathology alone can cause neurodegenerative disease. Mutations in the tau gene, microtubule-associated protein tau (MAPT), can cause autosomal dominant frontotemporal dementia, directly implicating tau dysfunction in neurodegeneration. In AD, tau loses its affinity for microtubules and aggregates, forming oligomers, paired helical filaments (PHF) and NFTs. Growing evidence suggests that neuronal loss precedes formation of NFTs and indicates that tau oligomers are the most toxic species. Recent findings have revealed that tau pathology mediates Aβ toxicity, as demonstrated in animal models. Suppression or reduction of tau in mice prevents or reduces the toxic effects of Aβ. Indeed, hippocampal neurons from tau knockout mice are resistant to Aβ-induced cell death, implicating a role of tau in Aβ-related neurodegeneration in AD. Moreover, reduction of tau levels prevented behavioral deficits in an AD mouse model without altering Aβ levels. Thus, removal of tau by immunization should be beneficial. On the other hand, immunotherapy targeting Aβ reduced amyloid pathology but cognitive decline persisted. Perhaps this is a consequence of the fact that treatment has little or no effect on tau pathology. This was demonstrated in human subjects immunized with Aβ peptide (AN1792), in whom removal of plaques had some effect in reducing phosphorylated tau in neuronal processes, but the poor effect on tau pathology was not enough to stop cognitive decline. This suggests that once tau pathology is initiated, it can self-propagate and removal of Aβ is insufficient. All of these findings highlight the need to target tau as an alternative treatment for AD.

Tau immunotherapy
Immunomodulation to clear tau pathology is an exciting approach for the treatment of AD. Currently, few reports on targeting tau by immunotherapy have been published. Active and passive immunizations were performed in AD mouse models. Chronic treatment with tau peptide as well as an antibody against phosphosites Ser396/404 cleared NFTs in P301L and htau/PS1 (M146L) mice. Further, vaccination of tau mutant mice with other phosphoepitopes such as Tau195-213 (P-202/205), Tau207-220 (P-212/214), Tau224-238 (P-231), and tau peptide (KSPVSGDTSPR) phosphorylated at serine S396/404, effectively reduced NFT pathology. Immunization targeting Phospho-Ser422 was also demonstrated in THY-Tau22 mice. Cognitive improvement was observed using the Y-maze, as was reduction of soluble tau from the brain. Conformational antibody-mediated clearance of aggregated tau has also been addressed. PHF1 and MC1 antibodies were used to treat JNPL3 and P301S mice. PHF1 recognizes phosphorylation at serine (396 and 404) and MC1 is a conformation-specific antibody that recognizes the amino acids 312–342 of tau protein. Treatment of 2-month-old mice showed a reduction of NFTs in the cortex/forebrain in the JNPL3 model, and lowered neurospheroids in P301L. Additionally, chronic treatment with MC1 and a sequence-specific antibody, DA31, was recently performed in the P301L mouse. MC1 significantly reduces total tau and insoluble tau in the brain, but not the DA31 antibody. These findings highlight the advantage of using conformational antibodies rather than sequence-specific antibodies. Further, given that tau is an endogenous protein with important
functions, it is essential to select the correct target to avoid removal of functional protein.

Although immunization targeting tau aggregates effectively removes NFTs, the effect of toxic tau oligomers has not been evaluated. Recently, we engineered an anti-tau oligomer-specific antibody (TOMA) that does not recognize monomeric functional tau or mature NFTs and has high affinity for tau oligomers. Immunization with the TOMA antibody reversed behavioral deficits observed in the P301L mouse. Additionally, we used TOMA antibody to evaluate the effect of removal of tau oligomers by immunotherapy in Tg2576 mice. Preliminary results show that reduction of tau oligomers improves cognitive deficits in an AD mouse model. Interestingly, Aβ*56 was also reduced in mice treated with TOMA. Our findings suggest that oligomeric tau may be interacting with Aβ*56 in this mouse model.

So far, there is still much to investigate about the toxic relationship between Aβ and tau. Moreover, it is important to consider the stage of the disease at the time of treatment. Recent developments in the field suggest that therapeutic interventions may be more effective in the asymptomatic phase of AD, and understanding how Aβ is involved at a very early stage may lead to better preventive treatments.

Perspectives
Important findings in the field have been made since Alois Alzheimer described the pathology of AD for the first time 100 years ago. Unfortunately, there is still no treatment to stop or reverse progression of the disease. Therapeutic approaches to treat AD are currently under investigation. So far, the results obtained targeting Aβ in preclinical studies did not correspond with those observed in clinical trials, and many factors should be considered, including the stage of disease at the time of therapy. The lack of substantial cognitive improvement obtained by targeting Aβ raises the question of whether or not this is the correct target. Aβ may initiate a cascade of events that at a certain stage becomes irreversible, thereby making removal of Aβ insufficient for halting cognitive decline. This could be the case of tau pathology, once initiated it is able to self-propagate, affecting neighboring or synaptically connected cells and inducing neuronal death. Tau is also necessary to mediate Aβ-induced toxicity, highlighting the potential of tau oligomers as a therapeutic target for AD.

Acknowledgment
The authors are grateful to Julia Gerson and Urmik Sen-Gupta for their useful suggestions in the preparation of this manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References

Dovepress

**ImmunoTargets and Therapy** downloaded from https://www.dovepress.com/ by 54.191.40.80 on 04-Jul-2017

For personal use only.


